Form 4: Whitehawk Therapeutics CEO Sells Shares

Whitehawk Therapeutics CEO David James Lennon reported a sale of 14,500 common shares for $3.38 each, totaling $49,010, to cover tax obligations related to vested restricted stock units.

Summary

• David James Lennon, CEO and Director of Whitehawk Therapeutics, Inc., sold 14,500 shares of common stock on April 9, 2026.
• The sale was executed at a price of $3.38 per share, resulting in a total transaction value of $49,010.
• This transaction was a broker-assisted sale to satisfy the reporting person's tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Lennon beneficially owns 518,622 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is for tax purposes related to vested RSUs, which is a common and expected transaction for executives, rather than a reflection of negative sentiment towards the company's prospects.

Positives

• The sale was conducted to cover tax obligations, indicating a planned and non-discretionary event related to executive compensation rather than a signal of negative sentiment.
• The CEO still beneficially owns a significant number of shares (518,622) after the transaction.

Negatives

• A sale of company stock by a CEO, even for tax purposes, can sometimes be perceived negatively by the market.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors regarding their stock transactions. While any sale can attract attention, the stated reason for this sale (tax withholding for vested RSUs) is a common and often expected event for executives.

Stakeholder Impact

• Shareholders: May observe the transaction, but the stated reason for the sale (tax withholding) mitigates concerns about insider selling based on negative company outlook. The CEO's continued significant beneficial ownership remains a positive signal.

Key Dates

Keywords

Whitehawk Therapeutics, WHWK, Form 4, Insider Trading, Stock Sale, CEO, David James Lennon, Restricted Stock Units, Tax Withholding